PreCursor-M+

Qualitative detection of promotor hypermethylation of 2 cervical cancer associated genes (FAM19A4 and hsa-miR124-2).

Identify HPV positive women with high short-term progression to (pre)cancer.

Special Features:

  • Sample types:
    • Bisulfite-converted DNA isolated from physician collected cervical specimens or self-collected vaginal specimens
  • Clinical performance - Long-term data:   
    • Most evaluated and validated methylation assay to identify HPV positive women with progressing cervical disease in direct need for colposcopy or other follow-up procedures1,2
    • Demonstrating very high sensitivity for cervical cancer detection (95.0-100%) in HPV-positive cervical specimens2,3,4
    • Longitudinal data: The long-term risk for cancer with a negative PreCursor-M+ is lower than with a negative cytology result; for CIN3 the long-term risk is similar as cytology5,6 
  • Flexible:
    • Suitable for various sample types, including self-samples and common Liquid Based Cytology media types
    • Compatible with standard DNA extraction methods
  • Reliable:     
    • Build-in check for sample quality ensuring reliable results 

Precursor-M+ is a registered trademark of the legal manufacturer, Self-screen B.V., the Netherlands, and is distributed by Fujirebio Europe.

CE marked
PreCursor-M+

Product number 81352

72 Tests
Please contact your local Fujirebio representative for the availability of this product in your country.
Self-screen Precursor-M+

Click here to navigate

  • Details
  • Conditions of sale
  • Citations
  • Documentation
  • Insights
  • Related products

  • Details

    Technical Specifications:

    • Method:
      • Multiplex real-time methylation-specific PCR assay
    • Target:
      • Promotor hypermethylation of 2 cervical cancer associated genes (FAM19A4 and hsa-miR124-2)
    • Sample types:
      • Cervical specimens stored in PreservCyt Solution or HC2 DNA Collection device
      • Self-collected vaginal brush/broom samples
    • Sample volume:
      • Input in the PreCursor-M+ reaction is 2.5 μL of bisulfite-converted DNA
    • Reaction time:
      • Total time to result: 4 - 24hrs. (incl. DNA extraction and bisulfite conversion; semi-automated or manual workflow)
        PreCursor-M+ assay:
      • Run time in real-time PCR cycler: within 90 minutes
      • Hands-on time: 20 minutes
    • Equipment:​​​​​​
      • Mic qPCR cycler (Bio Molecular Systems)
      • QPCR software (Bio Molecular Systems)
      • PreCursor-M+ v.1.0.mic template

     

    References:

    1. Kremer WW, Steenbergen RDM, Heideman DAM, Kenter GG, Meijer CJLM. The use of host cell DNA methylation analysis in the detection and management of women with advanced cervical intraepithelial neoplasia: a review. BJOG 2021;128:504-514
    2. Bonde J. et al. Int. J. Cancer. 2021;148:396-405. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study.

    3. Vink F.J. et al. Int J Cancer. 2020;147:1215-1221

    4. Hampl M. et al. Int J Cancer. 2022 ;1-8

    5. De Strooper et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14-year follow-up. Int. J. Cancer 2018;143(6):1541-1548 

    6. Dick et al. Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. Gynecol Oncol. 2019;154(2):368-373

  • Conditions of sale

    To read the end user conditions of sale for this product please visit our Resource center.

  • Citations

  • Insights

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.